Asia-Pacific consensus on long-term and sequential therapy for osteoporosis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tai Ta-Wei, Chen Hsuan-Yu, Shih Chien-An, Huang Chun-Feng, McCloskey Eugene, Lee Joon-Kiong, Yeap Swan Sim, Cheung Ching-Lung, Charatcharoenwitthaya Natthinee, Jaisamrarn Unnop, Kuptniratsaikul Vilai, Yang Rong-Sen, Lin Sung-Yen, Taguchi Akira, Mori Satoshi, Li-Yu Julie, Ang Seng Bin, Chan Ding-Cheng, Chan Wai Sin, Ng Hou, Chen Jung-Fu, Tu Shih-Te, Chuang Hai-Hua, Chang Yin-Fan, Chen Fang-Ping, Tsai Keh-Sung, Ebeling Peter R, Marin Fernando, Nistal Rodríguez Francisco Javier, Shi Huipeng, Hwang Kyu Ri, Kim Kwang-Kyoun, Chung Yoon-Sok, Reid Ian R, Chandran Manju, Ferrari Serge, Lewiecki E Michael, Hew Fen Lee, Ho-Pham Lan T, Nguyen Tuan Van, Nguyen Van Hy, Lekamwasam Sarath, Pandey Dipendra, Bhadada Sanjay, Chen Chung-Hwan, Hwang Jawl-Shan, Wu Chih-Hsing
Аннотация
METHODS: A panel of experts convened to develop consensus statements by synthesizing the current literature and leveraging clinical expertise. The review encompassed long-term anti-osteoporosis medication goals, first-line treatments for individuals at very high fracture risk, and the strategic integration of anabolic and antiresorptive agents in sequential therapy approaches.
RESULTS: The panelists reached a consensus on 12 statements. Key recommendations included advocating for anabolic agents as the first-line treatment for individuals at very high fracture risk and transitioning to antiresorptive agents following the completion of anabolic therapy. Anabolic therapy remains an option for individuals experiencing new fractures or persistent high fracture risk despite antiresorptive treatment. In cases of inadequate response, the consensus recommended considering a switch to more potent medications. The consensus also addressed the management of medication-related complications, proposing alternatives instead of discontinuation of treatment.
CONCLUSIONS: This consensus provides a comprehensive, cost-effective strategy for fracture prevention with an emphasis on shared decision-making and the incorporation of country-specific case management systems, such as fracture liaison services. It serves as a valuable guide for healthcare professionals in the Asia-Pacific region, contributing to the ongoing evolution of osteoporosis management.